Lumosa Therapeutics Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 4.59 million compared to TWD 0.634 million a year ago. Net loss was TWD 154.65 million compared to net income of TWD 468.89 million a year ago. Basic loss per share from continuing operations was TWD 0.95 compared to basic earnings per share from continuing operations of TWD 3.1 a year ago. Diluted loss per share from continuing operations was TWD 0.95 compared to diluted earnings per share from continuing operations of TWD 3.1 a year ago.
For the nine months, sales was TWD 12.29 million compared to TWD 7.3 million a year ago. Net loss was TWD 534.3 million compared to net income of TWD 424.11 million a year ago. Basic loss per share from continuing operations was TWD 3.29 compared to basic earnings per share from continuing operations of TWD 2.83 a year ago. Diluted loss per share from continuing operations was TWD 3.29 compared to diluted earnings per share from continuing operations of TWD 2.82 a year ago.